Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance Value.
Hawkins N. et al, (2025), Pharmacoecon Open
A systematic review of in vivo brain insulin resistance biomarkers in humans
Reid G. et al, (2025), Biomarkers in Neuropsychiatry, 12
Long-term outcomes following alternative second-line oral glucose-lowering treatments: Results from the real-world progression in type 2 diabetes mellitus United Kingdom (RAPIDS-UK) model.
Carroll OU. et al, (2025), Diabetes, obesity & metabolism
Glucocorticoid-induced hyperglycaemia in hospitalised adults: A matched cohort study (2013-2023).
Golubic R. et al, (2025), Diabetes Obes Metab
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.
Hanlon P. et al, (2025), JAMA, 333, 1062 - 1073
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
De Giorgi R. et al, (2025), Nature Mental Health, 3, 354 - 373
The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.
Adler AI. et al, (2025), Lancet, 405
Cardiovascular Risk Prediction Scores in Type 1 Diabetes: A Systematic Review and Meta-Analysis.
Erqou S. et al, (2025), JACC Adv, 4
Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations.
Lugo-Palacios DG. et al, (2025), Health Econ, 34, 85 - 104
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).
Lin B. et al, (2024), Lancet Diabetes Endocrinol, 12, 904 - 914
The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors.
Klonoff DC. et al, (2024), J Diabetes Sci Technol, 18, 1346 - 1361
Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge.
Altunkaya J. et al, (2024), Value Health, 27, 1338 - 1347
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling WHK. et al, (2024), PLoS Med, 21
12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.
De Giorgi R. et al, (2024), EClinicalMedicine, 74
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Adler AI. et al, (2024), Lancet, 404, 145 - 155
ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.
Sammons EL. et al, (2024), Ophthalmology, 131, 771 - 779